Cuorips Inc. Stock

Equities

4894

JP3266030000

Pharmaceuticals

Delayed Japan Exchange 12:05:49 2024-06-05 am EDT 5-day change 1st Jan Change
5,130 JPY -0.39% Intraday chart for Cuorips Inc. -1.72% +121.03%
Sales 2022 13 2.02K Sales 2023 38 5.91K Capitalization 255M 39.59B
Net income 2022 -375M -58.29B Net income 2023 -452M -70.26B EV / Sales 2022 * -
Net cash position 2022 * - 0 Net cash position 2023 * - 0 EV / Sales 2023 * -
P/E ratio 2022 *
-
P/E ratio 2023 *
-
Employees 43
Yield 2022 *
-
Yield 2023 *
-
Free-Float 71.16%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.52%
1 week-3.83%
Current month-0.20%
1 month+43.43%
3 months+34.22%
6 months+180.45%
Current year+116.29%
More quotes
1 week
4 750.00
Extreme 4750
6 180.00
1 month
2 780.00
Extreme 2780
6 180.00
Current year
1 952.00
Extreme 1952
6 180.00
1 year
1 287.00
Extreme 1287
6 180.00
3 years
1 287.00
Extreme 1287
6 180.00
5 years
1 287.00
Extreme 1287
6 180.00
10 years
1 287.00
Extreme 1287
6 180.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 65 20-05-31
Chief Tech/Sci/R&D Officer 68 21-07-31
Chief Administrative Officer 68 17-06-30
Members of the board TitleAgeSince
Director/Board Member 65 20-11-30
Chief Executive Officer 65 20-05-31
Chief Administrative Officer 68 17-06-30
More insiders
Cuorips Inc is a Japan-based company mainly engaged in the development and commercialization of regenerative medical products and contract development and manufacturing organization (CDMO) business. The main product of the Company is human iPS cell-derived cardiomyocyte sheets. The Company provides regenerative medical products for the heart and other areas through in-house research, joint research with universities and other research institutions and major pharmaceutical companies. The Company operates CDMO business using CLiC-1, a commercial cell culture and processing facility with an integrated laboratory based on the Company's original design concept.
More about the company

Annual profits - Rate of surprise